Tag Archives: COPD

FRI shows clinically meaningful benefits of Bevespi in COPD

We are happy to announce that a few days ago the positive results of AstraZeneca’s Bevespi (LABA/LAMA), compared to placebo have been published in the International Journal of COPD. The study shows how FRI confirmed the strong, homogeneous effect of the innovative co-suspension bronchodilator compared to placebo, as seen in earlier studies. At the same time, the results indicate the strong relationship between the FRI endpoints (changes in airway resistance) and clinical endpoints (changes in FEV1), highlighting the clinical relevance of the FRI endpoints once again.

 

GFF MDI (n=20) Placebo MDI (n=19) LSM ratio of GFF MDI vs placebo MDI P-value
No of patients/no of lobes 19/92 19/92 19/92 19/92
Geometric LSM 0.09 0.30 0.29 <0.0001
(95% CI) (0.07-0.11) (0.23-0.40) (0.25-0.33)

Abbreviations: GFF, glycopyrrolate/formoterol fumarate; LSM, least squares mean; MDI, metered dose inhaler; siRaw, specific image-based airway resistance; TLC, total lung capacity.

Figure 1: Functional respiratory imaging co-primary endpoint: siRaw at TLC on Day 15 (kPa⋅s; intent-to-treat population).

This study forms the basis to investigate the effect and added value of LABA, LAMA and ICS, either separately or in combination. The enhanced sensitivity of the FRI parameters (>70% signal versus <30% signal in FEV1) allows for smaller, shorter and less expensive trials.

Click here to read the full study, and contact us now if you wish to receive more information around FRI in clinical trials for therapy analysis.

ATS Conference 2018 | 18-23 May | San Diego, CA

Not only will FLUIDDA present at the first Respiratory Innovation Summit at the American Thoracic Society conference 2018, we also have a strong scientific program with 7 Functional Respiratory Imaging  related presentations. Looking forward to seeing you at booth 2542!   Sunday, May 20     Monday, May 21             Tuesday, May… Continue Reading

Joint forces for Value Based Healthcare

We are proud to announce that we’ve signed a Memorandum of Understanding with Ciro to join forces to improve patient-care of COPD patients in the Netherlands. We both share the same vision around personalised medicine: customised to the patient with a Value Based Healthcare approach. Value-based healthcare is a healthcare delivery model in which providers,… Continue Reading

Introduction to Functional Respiratory Imaging (FRI) for Investors and Market Analysts

For those who cannot attend our event coming Thursday at Flanders House in New York, you are welcome to register for the Webcast via following link: https://attendee.gotowebinar.com/register/8186175617140384514       FLUIDDA is delighted to invite you to a dedicated session discussing her proprietary Functional Respiratory Imaging (FRI) technology and its application in drug and device… Continue Reading

FLUIDDA’s FRI Technology was used in a Positive Phase II Trial with iNOpulse® for Treatment of Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD)

“Functional Respiratory Imaging (FRI) provided valuable insights throughout the development process of iNO in COPD patients with PH. The therapy was effective in the initial studies and has great potential to improve the lives of these severely affected patients” Dr. J. De Backer, CEO FLUIDDA   Changes in Blood Vessel Volume determined using Functional Respiratory… Continue Reading

FLUIDDA’s FRI technology will shine throughout ERS 2017

As the European Respiratory Society Conference is approaching rapidly, FLUIDDA is proud to announce that a total of 9 abstracts will be presented, highlighting the power of Functional Respiratory Imaging (FRI). FRI capabilities will be presented over a range of applications including: drug delivery optimization bronchodilation and non-invasive ventilation in COPD bronchoconstriction in asthma disease… Continue Reading

Study demonstrates validity and utility of FRI-based V/Q

Exciting new results will be presented at the upcoming European Respiratory Society Conference in Milan from 9-13 September! The primary function of the respiratory system is the transfer oxygen from the environment into the blood stream of a individual. Consequently in a healthy subject the regional ventilation in the lungs is well matched to the… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2017